DEF: Fortress Biotech Seeks Stockholder Approval for Officer Exculpation and Director Elections at 2025 Annual Meeting

Fortress Biotech is holding its annual stockholder meeting on June 17, 2025, to elect directors, ratify the accounting firm, approve executive compensation, and amend the corporate charter to include officer exculpation.

Summary

• Fortress Biotech will hold its Annual Meeting of Stockholders virtually on June 17, 2025, at 10:00 a.m. ET.
• Stockholders will vote to elect seven directors for a one-year term.
• They will also ratify the appointment of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2025.
• An advisory vote will be held to approve the compensation of the named executive officers.
• Stockholders will also vote on the frequency of advisory votes on executive compensation.
• A key proposal involves approving the Second Amended and Restated Certificate of Incorporation to provide for officer exculpation.
• The board recommends voting in favor of all director nominees, ratifying KPMG, approving executive compensation, selecting a three-year frequency for advisory votes, and approving the amended certificate of incorporation.
• As of April 17, 2025, directors and executive officers owned approximately 27.9% of the outstanding common stock.
• KPMG billed approximately $3,785,420 in audit fees for the fiscal year ended December 31, 2024, including fees for partner companies and subsidiaries.
• The company has adopted a Clawback Policy for incentive-based compensation.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral tone. The proposals are generally positive for corporate governance and management protection, but the company's financial performance is a concern.

Positives

• The proposal to provide officer exculpation aims to attract and retain qualified officers by offering them similar liability protection as directors.
• The company has a Clawback Policy in place to recover erroneously awarded incentive-based compensation.
• The virtual format of the annual meeting facilitates greater shareholder access.
• The board is recommending a three-year frequency for say-on-pay votes, which they believe provides a long-term perspective for evaluating compensation programs.

Negatives

• The company's net income has been negative for the past three fiscal years, with a net loss of $121 million in 2024.
• Audit fees from KPMG were significant, totaling $3,785,420 in 2024.

Risks

• Failure to approve the officer exculpation amendment may hinder the company's ability to attract and retain qualified officers.
• The company's reliance on related-party transactions, such as shared services agreements, could pose potential conflicts of interest.
• The company's net losses could impact its ability to pay dividends or fund operations.
• The company's dependence on key personnel, such as Dr. Rosenwald and Mr. Weiss, could pose a risk if they were to leave the company.

Future Outlook

The document outlines proposals for the upcoming annual meeting, including director elections, auditor ratification, executive compensation approval, and a corporate charter amendment. The outcomes of these votes will shape the company's governance and operational structure.

Management Comments

• Lindsay A. Rosenwald, M.D., Executive Chairman, Chief Executive Officer and President, encourages stockholders to vote.
• The Board of Directors believes that exculpation provisions empower both directors and officers to exercise their best judgment in furtherance of stockholder interests.

Industry Context

The proposal to adopt officer exculpation aligns Fortress Biotech with a growing trend among Delaware corporations to provide similar protections for officers as for directors, addressing rising litigation and insurance costs. This is particularly relevant in the biopharmaceutical industry, where decision-making often involves significant risk and potential liability.

Comparison to Industry Standards

• The executive compensation structure, including base salaries, bonuses, and equity-based awards, is typical for biotechnology companies of similar size and stage of development.
• The audit fees paid to KPMG are comparable to those of other publicly traded biopharmaceutical companies with similar complexity and scope of operations.
• The level of stock ownership by directors and executive officers is within the range observed at other companies in the industry, aligning management's interests with those of shareholders.
• The adoption of officer exculpation is becoming increasingly common among Delaware corporations, including those in the biotechnology sector, to attract and retain qualified executives.

Management Changes

Corporate Governance

Related Party Transactions

• The company has entered into shared services agreements with TGTX and Journey, which involve cost-sharing for employees and office space.
• The company has founders agreements with partner companies and subsidiaries, which include provisions for equity fees, cash fees, and change in control fees.
• The company has management services agreements with partner companies and subsidiaries, which involve the provision of advisory, consulting, and strategic services.

Stakeholder Impact

• Approval of the officer exculpation amendment could benefit officers by limiting their personal liability.
• The outcome of the executive compensation advisory vote could influence future compensation decisions.
• The election of directors will determine the composition of the board and its oversight of the company.
• The ratification of KPMG as the independent accounting firm will ensure the integrity of the company's financial reporting.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on June 17, 2025.
• The company will file a Form 8-K with the SEC to disclose the voting results within four business days of the Annual Meeting.
• If approved, the Second Amended and Restated Certificate of Incorporation will be filed with the Secretary of State of the State of Delaware.

Key Dates

Keywords

Fortress Biotech, proxy statement, annual meeting, directors, executive compensation, officer exculpation, KPMG, audit fees, stockholders, corporate governance